Regenerative medicine

3D BioFibR Appoints Dr. Michael Francis as Independent Board Member

Retrieved on: 
Monday, December 4, 2023
Technology, Textiles, Engineering, Genetics, Nanotechnology, Manufacturing, Biotechnology, Health, Pharmaceutical, Research, AFWERX, Zimmer Biomet, DARPA, Regenerative medicine, Tissue engineering, Army, NIH, 3D printing

3D BioFibR Inc. (“3D BioFibR”), a leading innovator in the field of tissue engineering and regenerative medicine, today announced that it has appointed Michael Francis, Ph.D., to its Board of Directors.

Key Points: 
  • 3D BioFibR Inc. (“3D BioFibR”), a leading innovator in the field of tissue engineering and regenerative medicine, today announced that it has appointed Michael Francis, Ph.D., to its Board of Directors.
  • Dr. Francis brings a wealth of experience in research and development and partnering of novel products using advanced collagen fiber manufacturing technologies.
  • Kevin Sullivan, CEO of 3D BioFibR said, “We are pleased to welcome Michael to 3D BioFibR’s Board.
  • “3D BioFibR is advancing a completely novel way of manufacturing collagen fibers for the tissue engineering and regenerative medicine market,” said Dr. Francis.

United States Regenerative Medicine Market Report 2023-2028: Robust Product Pipeline in Gene Therapies, Cell Therapies, Tissue Engineering Driving Demand - ResearchAndMarkets.com

Retrieved on: 
Wednesday, November 29, 2023
Biotechnology, Pharmaceutical, Health, Regenerative medicine, Human body, Conditional sentence, Incidence, Parkinson's disease, Gene, Competition, Investment, Tissue, Genomics, Insurance, Patient, DSM-IV codes, FDA, Tissue engineering, Genetic, Genetic disorder, Organ transplantation, Burns, Development, 3D bioprinting, Quality of life, Injury, Pharmaceutical industry, Vaccine, Health care, Veterinary medicine, 3D printing, Research

The "United States Regenerative Medicine Market, Competition, Forecast and Opportunities, 2018-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "United States Regenerative Medicine Market, Competition, Forecast and Opportunities, 2018-2028" report has been added to ResearchAndMarkets.com's offering.
  • The increasing adoption of stem cell technology, technological advancements, and a strong product pipeline are driving the demand for regenerative medicine.
  • Strong Product Pipeline: A robust product pipeline in gene therapies, cell therapies, tissue engineering, and more is driving demand for regenerative medicine.
  • Company Profiles: Detailed analysis of the major companies present in the United States Regenerative Medicine Market.

Weill Cornell Medicine to Open Medical Research Center at 1334 York Avenue

Retrieved on: 
Tuesday, November 28, 2023
Research, Commercial Building & Real Estate, Nursing, Construction & Property, Hospitals, Practice Management, Managed Care, General Health, Health, Science, Medicine, DNA, Weill Cornell Medicine, Disease, Cornell University, Clinical trial, NewYork-Presbyterian Queens, Laboratory, Weill Cornell Medical Center, Patient, Multimedia, Regenerative medicine, Mining, Algorithm, Heart, Intelligence, Machine learning, Neuroscience, Blood, Houston Methodist Hospital, Sotheby's, Weill, Cancer, Population health, LEED, Biophysical environment, NewYork-Presbyterian Brooklyn Methodist Hospital, Immunotherapy, Physician, Certification, Education, Hospital, Pharmaceutical industry, NewYork-Presbyterian Hospital

Weill Cornell Medicine is dramatically expanding its campus and research footprint in New York City by securing five floors of 1334 York Ave., the current home of Sotheby's auction house, the institution announced today.

Key Points: 
  • Weill Cornell Medicine is dramatically expanding its campus and research footprint in New York City by securing five floors of 1334 York Ave., the current home of Sotheby's auction house, the institution announced today.
  • Weill Cornell Medicine is committed to excellence in patient care, scientific discovery and the education of future physicians in New York City and around the world.
  • The doctors and scientists of Weill Cornell Medicine—faculty from Weill Cornell Medical College, Weill Cornell Graduate School of Medical Sciences, and Weill Cornell Physician Organization—are engaged in world-class clinical care and cutting-edge research that connect patients to the latest treatment innovations and prevention strategies.
  • Weill Cornell Medicine faculty provide exemplary patient care at NewYork-Presbyterian/Weill Cornell Medical Center, NewYork-Presbyterian Westchester Behavioral Health Center, NewYork-Presbyterian Lower Manhattan Hospital, NewYork-Presbyterian Queens and NewYork-Presbyterian Brooklyn Methodist Hospital.

SolasCure Demonstrates Proof-of-Concept in Phase lla Safety Trial of Aurase Wound Gel

Retrieved on: 
Tuesday, December 12, 2023
Science, Biotechnology, Research, Pharmaceutical, Surgery, Health, Medical Devices, Clinical Trials, Harvard University, Safety, Simon Business School, University of Zurich, Senior, Erythema, INN, EIC, Patient, University of Rochester, Regenerative medicine, Medical Affairs Bureau, Wound healing, MBA, Bleeding, University, Phase, Debridement, Growth, Medicine, Doctor of Philosophy, Edema, Hydrogel, Pharmaceutical industry, Nursing, Boston, Dermatology

The CLEANVLU trial evaluated the Company’s first investigational product, Aurase Wound Gel, for use in chronic venous leg ulcer patients over 12 applications of the product (dosed every 3 days).

Key Points: 
  • The CLEANVLU trial evaluated the Company’s first investigational product, Aurase Wound Gel, for use in chronic venous leg ulcer patients over 12 applications of the product (dosed every 3 days).
  • SolasCure’s CLEANVLU Phase IIa clinical trial observed a strong safety profile for Aurase Wound Gel, with no evidence of systemic availability, no antibody generation to the enzyme and no effects on systemic coagulation pathways.
  • SolasCure’s Aurase Wound Gel, a hydrogel containing an enzyme cloned from medical maggots, aims to facilitate debridement, reduce bacterial biofilm, and promote wound bed preparation and healing.
  • Aurase Wound Gel is due to enter further Phase II trials to further evaluate its efficacy across a larger and more diverse patient group than the Phase IIa study, with the positive safety data obtained from the Phase IIa trial allowing for higher concentrations of the gel to now be explored.

Aspect Biosystems Named to Fast Company’s 2023 List of the Next Big Things in Tech

Retrieved on: 
Tuesday, November 28, 2023
Biotechnology, Health Technology, Health, Medical Devices, Intelligence, Obesity, Disease, Therapy, Diabetes, Patient, Organization, Regenerative medicine, Aspect, BioSystems, Novo Nordisk, Partnership, Pharmaceutical industry

Aspect Biosystems is applying its full-stack tissue therapeutic platform to develop a novel class of cell-based tissue therapeutics that are biologically functional, immune protective, and suitable for surgical implantation.

Key Points: 
  • Aspect Biosystems is applying its full-stack tissue therapeutic platform to develop a novel class of cell-based tissue therapeutics that are biologically functional, immune protective, and suitable for surgical implantation.
  • Earlier this year, Aspect announced a precedent-setting partnership with Novo Nordisk worth over US$2.6 billion to develop bioprinted tissue therapeutics for diabetes and obesity.
  • “We’re honored to accept this recognition from Fast Company,” said Tamer Mohamed, CEO and co-founder of Aspect Biosystems.
  • We are thrilled to honor the organizations that are making them a reality.”
    Click here to see the final list.

Therapeutic Solutions International and Campbell Neurosciences Publish on Nutritional Modulation of the Indolamine 2,3 Dioxygenase Pathway as a Non-Toxic Means of Addressing Depression

Retrieved on: 
Monday, November 27, 2023
Biotechnology, Pharmaceutical, Health, Mental Health, Mental health, Perception, COVID-19, Depression, TSOI, Regenerative medicine, Science, Pharmaceutical industry, Medical device

Therapeutic Solutions International, Inc. (TSOI), announced today a publication with Campbell Neurosciences and several academic institutions describing the importance of the indolamine 2,3 dioxygenase pathway in depression, as well as modulation of this pathway by QuadraMune®, a multi-patented nutraceutical that is commercially available.

Key Points: 
  • Therapeutic Solutions International, Inc. (TSOI), announced today a publication with Campbell Neurosciences and several academic institutions describing the importance of the indolamine 2,3 dioxygenase pathway in depression, as well as modulation of this pathway by QuadraMune®, a multi-patented nutraceutical that is commercially available.
  • “QuadraMune® was developed as an immune stimulator for the prevention and treatment of COVID-19 and was granted several patents for this indication1,2.
  • Subsequently, the science behind QuadraMune® was validated by numerous independent institutions3,4,” said Thomas Ichim, Ph.D., President, and Chief Executive Officer of Campbell Neurosciences and Board Member of Therapeutic Solutions International.
  • Campbell Neurosciences is a subsidiary of Therapeutic Solutions International and has developed a blood-based test for suicidal propensity, as well as several therapeutic approaches to immunologically address mental health.

Satellos Bioscience Announces 2023 Q3 Financial Results and Operational Highlights

Retrieved on: 
Wednesday, November 22, 2023
Biotechnology, General Health, Pharmaceutical, Health, AAK1, Strategic management, GMP, Chemistry, Senior, MSCL, CFO, Bank statement, CMA, Regenerative medicine, Research, G&A, Therapy, MBA, Lead, Hand, MD, Michael Cross, CPA, Doctor of Philosophy, Duchenne muscular dystrophy, Travel, Pharmaceutical industry, Cryptocurrency, Duchenne, IND

Satellos Bioscience Inc. (TSXV: MSCL) (“Satellos” or the “Company”), a regenerative medicine company aimed at developing therapeutics that change the way degenerative muscle diseases are treated, announced today its financial results and operational highlights for the three months ending September 30, 2023.

Key Points: 
  • Satellos Bioscience Inc. (TSXV: MSCL) (“Satellos” or the “Company”), a regenerative medicine company aimed at developing therapeutics that change the way degenerative muscle diseases are treated, announced today its financial results and operational highlights for the three months ending September 30, 2023.
  • Satellos also announced that SAT-3247 would be nominated as the lead DC based on results generated by the Company during its preclinical studies.
  • Satellos had cash and cash equivalents of $44.3 million as of September 30, 2023, compared with $1.9 million at December 31, 2022.
  • Satellos’ interim condensed consolidated financial statements for the three and nine months ended September 30, 2023, and the related management’s discussion and analysis (MD&A) are available on SEDAR+ at www.sedarplus.ca .

RION, Mayo Clinic, and the U.S. Army Medical Research Institute for Chemical Defense Receive $2.4M Department of Defense Award to Advance Exosome-Based Research in Pulmonary Therapeutics

Retrieved on: 
Monday, November 20, 2023
Other Health, Research, Technology, Defense, Hospitals, Clinical Trials, Science, Nanotechnology, Biotechnology, Veterans, Health, Military, COPD, Prevalence, Disease, ICD, Mortality, DSM-IV codes, Patient, Multimedia, Regenerative medicine, Exosome, FDA, Particulates, Wound healing, Smoke, Inhalation, Therapy, Chronic obstructive pulmonary disease, Veteran, Splenic infarction, Chemical defense, Injury, Mayo Clinic, Fire, Pharmaceutical industry

RION, a leading clinical-stage regenerative medicine company, today announced that it will collaborate with Mayo Clinic and the U.S. Army Medical Research Institute for Chemical Defense (ICD) on a $2.4M grant awarded from the Department of Defense.

Key Points: 
  • RION, a leading clinical-stage regenerative medicine company, today announced that it will collaborate with Mayo Clinic and the U.S. Army Medical Research Institute for Chemical Defense (ICD) on a $2.4M grant awarded from the Department of Defense.
  • View the full release here: https://www.businesswire.com/news/home/20231120732351/en/
    RION, located in Rochester, MN, brings extensive experience in developing and commercializing biological therapeutics.
  • The harmful gases, vapors, and/or particulate matter released by fires in war zones typically results in severe lung-induced morbidity and mortality.
  • Recent discoveries have proven that exosomes, nano-sized vesicles known for their regenerative capabilities, play a crucial role in the human body.

Regenerative Medicine Collaboration and Licensing Agreements Analysis Report 2023 with a Directory of 1,651 Deals Signed Since 2016 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, November 15, 2023
Biotechnology, Health, Science, Pharmaceutical, Research, Regenerative medicine, Record, Confidentiality, Chapter Six, Intellectual property, Chapter Five, A-Z, Chapter Two, Chapter Four, Hyperlink, Chapter Three, Directory, Chapter One, Veterinary medicine, Risk management, Real estate, Property management, Commercial property, Lease

This report contains a comprehensive listing of 1651 regenerative medicine deals announced since 2016 including financial terms where available, including links to online deal records of actual regenerative medicine partnering deals as disclosed by the deal parties.

Key Points: 
  • This report contains a comprehensive listing of 1651 regenerative medicine deals announced since 2016 including financial terms where available, including links to online deal records of actual regenerative medicine partnering deals as disclosed by the deal parties.
  • Regenerative Medicine Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the regenerative medicine deals entered into by the worlds leading biopharma companies.
  • Fully revised and updated, the report provides details of regenerative medicine deals from 2016 to 2023.
  • The report provides a detailed understanding and analysis of how and why companies enter regenerative medicine deals.

Athersys Reports Third Quarter 2023 Financial Results and Business Highlights

Retrieved on: 
Thursday, November 16, 2023
Health, FDA, Stem Cells, Genetics, Clinical Trials, Pharmaceutical, Biotechnology, Shift, Ardent Health Services, Acquisition, Exercise, Clinical trial, Patient, Regenerative medicine, Research, Stroke, Operational definition, OTC, MOU, Pharmaceutical industry, Cryptocurrency

Athersys, Inc. (OTC: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) cell therapy for critical care indications, announced financial results for the three and nine months ended September 30, 2023 and provided a business update.

Key Points: 
  • Athersys, Inc. (OTC: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) cell therapy for critical care indications, announced financial results for the three and nine months ended September 30, 2023 and provided a business update.
  • There was no revenue for the third quarter of 2023 compared with $0.1 million for the third quarter of 2022, which included the delivery of services under the arrangement with Healios.
  • Research and development expenses were $4.0 million for the third quarter of 2023 compared with $12.4 million for the comparable period in 2022.
  • Cash and cash equivalents were $1.0 million as of September 30, 2023, compared with $9.0 million as of December 31, 2022.